Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

By targeting a cancer-driving pathway at multiple steps, a triple therapy stopped pancreatic tumors from developing ...

Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented ...

Current drugs for pancreatic cancer lose effectiveness within months because the tumor becomes resistant. Now, a group from Spain's National Cancer Research Centre (CNIO) has been able to avoid the ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants. The study, published in Cancer ...

A group of researchers says they have made a major breakthrough toward finding a cure for pancreatic cancer. They wrote in a ...

Current drugs for pancreatic cancer lose effectiveness within months because the tumour becomes resistant. The group from ...

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.

Spanish researchers achieved complete pancreatic tumor elimination in mice using a triple-drug strategy targeting KRAS and ...

By targeting three key growth pathways at once, researchers eliminated pancreatic tumors in multiple mouse models and ...